A5011286789- Sarcoma Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Cellular Mechanics and Interactions
- Tissue Engineering and Regenerative Medicine
- Cancer Cells and Metastasis
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Urologic and reproductive health conditions
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Silk-based biomaterials and applications
- Lymphoma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- RNA Research and Splicing
- Soft tissue tumor case studies
- Molecular Biology Techniques and Applications
- Immune Cell Function and Interaction
- Advanced Proteomics Techniques and Applications
- Tumors and Oncological Cases
- Cancer-related gene regulation
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Meningioma and schwannoma management
- Bone Tumor Diagnosis and Treatments
- Viral-associated cancers and disorders
The Christie Hospital
2023-2024
St Mary's Hospital
2024
The Christie NHS Foundation Trust
2022-2024
Manchester Academic Health Science Centre
2024
Institute of Cancer Research
2016-2023
Royal Marsden NHS Foundation Trust
2015-2021
Royal Marsden Hospital
2015-2020
University of California, San Francisco
2018
City College of San Francisco
2017
Fred Hutch Cancer Center
2016
Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed selinexor. We evaluated the clinical benefit selinexor previously treated DD-LPS whose sarcoma progressed on approved agents.
Abstract Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological subtypes. Within leiomyosarcomas, identify three subtypes distinct myogenesis immune features, anatomical site distribution survival outcomes. Characterisation undifferentiated pleomorphic dedifferentiated liposarcomas low infiltrating CD3 + T-lymphocyte levels...
Abstract Chromatin accessibility is a crucial driver of cellular plasticity, priming gene expression and defining distinct states. Variability in chromatin significant determinant epigenetic transcriptional regulation can reveal clinically relevant subtypes biomarkers therapy response. In osteosarcoma (OS), we identified two subtypes, EC1 EC2, using ATAC-seq analysis. These are defined by differential circuitry, with characterized developmental transcription factors such as RUNX2, MEF2C,...
The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype soft tissue sarcoma that exhibits histological heterogeneity, is not established. use microarrays (TMA) studies profile TIL burden attractive but given the potential for intra-tumoural heterogeneity to introduce sampling errors, adequacy this approach undetermined. In study, we assessed inter- within retrospective cohort primary LMS specimens. Using virtual TMA approach,...
The landscape of extracellular matrix (ECM) alterations in soft tissue sarcomas (STS) remains poorly characterized. We aimed to investigate the tumor ECM and adhesion signaling networks present STS their clinical implications. Proteomic data from 321 patients across 11 histological subtypes were analyzed define integrin networks. Subgroup analysis was performed leiomyosarcomas (LMS), dedifferentiated liposarcomas (DDLPS), undifferentiated pleomorphic (UPS). This defined subtype-specific...
Abstract Background Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. Methods Axi-STS was a pathologically-stratified, non-randomised, open-label, multi-centre, phase II trial of continuous axitinib treatment patients ≥16 years, performance status ≤2, pathologically-confirmed advanced/metastatic soft tissue sarcoma (STS). Patients were recruited within four tumour strata, each analysed separately:...
Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic epigenomic profiling STS have been undertaken, proteomic analysis has thus far limited. Here we utilise sequential window acquisition all theoretical fragment ion spectra mass spectrometry (SWATH-MS) for formalin fixed paraffin embedded (FFPE) specimens from cohort patients (n = 36) across four histological subtypes (leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma...
Despite the advances taking place for patients with many types of cancer, to date there has been little success in meeting great need novel treatments advanced soft tissue sarcoma effective immunologic therapies. Here, we review recent clinical and preclinical data that indicate immune responses against sarcomas occur spontaneously can also be successfully provoked. Efforts manipulate microenvironment have potential eradicate disease may sensitize tumors other tumor-targeted...
Abstract Testicular germ cell tumours (TGCT), which comprise seminoma and non-seminoma subtypes, are the most common cancers in young men. In this study, we present a comprehensive whole genome sequencing analysis of adult TGCTs. Leveraging samples from participants recruited via UK National Health Service data Genomics England 100,000 Genomes Project, our results provide an extended description genomic elements underlying TGCT pathogenesis. This catalogue offers comprehensive,...
The aim of the study was to report outcome primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with LGFMS, SEF, or H-LGFMS/SEF, surgically treated curative intent from January 2000 September 2022, were enrolled 14 countries 27 institutions. Pathologic inclusion criteria predefined by expert pathologists. endpoint overall survival (OS). Secondary endpoints crude cumulative incidence (CCI) local...
The exploration and identification of new anti-cancer therapeutic indications for an approved drug already in use, or a that was shelved non-safety reasons early clinical development, represents attractive alternative to the costly, time-consuming inefficient process developing novel anticancer agents. Drug repositioning repurposing can bypass discovery phases cancer potentially reducing hundreds millions dollars more than decade typically required see agent through regulatory approval....
Despite the advances taking place for patients with many types of cancer, to date there has been little success in meeting great need novel treatments advanced soft tissue sarcoma effective immunologic therapies. Here, we review recent clinical and preclinical data that indicate immune responses against sarcomas occur spontaneously can also be successfully provoked. Efforts manipulate microenvironment have potential eradicate disease may sensitize tumors other tumor-targeted...
<p>Supplemental Methods</p>